- Home
- ACIU vs INV Comparison
ACIU vs INV Comparison
Compare ACIU & INV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- INV
- Stock Information
- Founded
- ACIU 2003
- INV 2015
- Country
- ACIU Switzerland
- INV United States
- Employees
- ACIU N/A
- INV N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- INV
- Sector
- ACIU Health Care
- INV
- Exchange
- ACIU Nasdaq
- INV NYSE
- Market Cap
- ACIU 189.1M
- INV 173.3M
- IPO Year
- ACIU 2016
- INV N/A
- Fundamental
- Price
- ACIU $2.07
- INV $4.93
- Analyst Decision
- ACIU Strong Buy
- INV Strong Buy
- Analyst Count
- ACIU 1
- INV 2
- Target Price
- ACIU $12.00
- INV $14.00
- AVG Volume (30 Days)
- ACIU 139.5K
- INV 184.1K
- Earning Date
- ACIU 08-05-2025
- INV 08-15-2025
- Dividend Yield
- ACIU N/A
- INV N/A
- EPS Growth
- ACIU N/A
- INV N/A
- EPS
- ACIU N/A
- INV N/A
- Revenue
- ACIU $32,014,254.00
- INV $1,220,000.00
- Revenue This Year
- ACIU N/A
- INV $1,045.66
- Revenue Next Year
- ACIU $533.21
- INV $240.46
- P/E Ratio
- ACIU N/A
- INV N/A
- Revenue Growth
- ACIU 91.20
- INV 18.27
- 52 Week Low
- ACIU $1.43
- INV $3.00
- 52 Week High
- ACIU $4.26
- INV $18.75
- Technical
- Relative Strength Index (RSI)
- ACIU 56.20
- INV N/A
- Support Level
- ACIU $1.65
- INV N/A
- Resistance Level
- ACIU $2.17
- INV N/A
- Average True Range (ATR)
- ACIU 0.17
- INV 0.00
- MACD
- ACIU -0.01
- INV 0.00
- Stochastic Oscillator
- ACIU 70.37
- INV 0.00
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About INV INNVENTURE INC
Innventure Inc creates, funds, operates, and rapidly scales companies in strategic collaboration with MNCs. It provides company creation, corporate strategy, technology optimization, operations, commercialization, and funding. Innventure analyzes the market, including proprietary data provided by MNCs, to identify where their well-protected, breakthrough technologies address market needs and have the potential to create $1B+ in new enterprise value.